These benefits, along with a earlier report displaying that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like actions in mice,2 help the principle of targeting ACKR3 as a unique method to modulate the opioid program, which could open new therapeutic avenues for opioid-linked Proble